MENLO PARK, Calif., July 10, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM ), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that on July 9, 2018, the company granted inducement awards to 9 new employees. The grants were made pursuant to Dermira’s 2018 Equity Inducement Plan as an inducement material to the employees’ acceptance of employment with Dermira and were approved by the Compensation Committee of Dermira’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4).

The company granted restricted stock unit awards (RSUs) representing an aggregate of 6,250 shares of Dermira common stock and stock options to purchase an aggregate of 27,150 shares of Dermira common stock.

One-third of the total number of shares subject to the RSUs will vest on August 15, 2019, and annually thereafter, respectively, until fully vested on the third anniversary, subject to the employee’s continued service with Dermira on each such vesting date. One-fourth of the total number of shares underlying the stock options will vest on the one-year anniversary of the employee’s date of hire and 1/48 th of the total number of shares underlying the stock options will vest each month thereafter until fully vested on the fourth anniversary of the employee’s date of hire, subject to the employee’s continued service with Dermira on each such vesting date. The stock options have a term of ten years and an exercise price of $10.42 per share, which is equal to the closing price of Dermira’s common stock on the grant date as reported by the Nasdaq Global Select Market.

About Dermira Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. Dermira is committed to understanding the needs of both patients and physicians and using its insight to identify and develop leading-edge medical dermatology programs. The company’s approved treatment, Qbrexza™ (glycopyrronium) cloth, is an anticholinergic indicated for the topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older. Primary axillary hyperhidrosis is excessive underarm sweating with no known cause and beyond what is needed for normal body temperature regulation. Dermira is also evaluating lebrikizumab in a Phase 2b clinical trial for the treatment of moderate-to-severe atopic dermatitis (a severe form of eczema) and has early-stage research programs in other areas of dermatology. Dermira is headquartered in Menlo Park, Calif. For more information, please visit  http://www.dermira.com . Follow Dermira on  Twitter  and  LinkedIn .

In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Dermira uses its website ( www.dermira.com ), LinkedIn page ( https://www.linkedin.com/company/dermira-inc- ) and corporate Twitter account (@DermiraInc) as channels of distribution of information about its company, product candidates, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Dermira may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Dermira’s website, LinkedIn page and Twitter account in addition to following its SEC filings, news releases, public conference calls and webcasts.

Contacts:

Media: Erica Jefferson Vice President, Corporate Communications 650-421-7216 media@dermira.com

Investors: Ian Clements, Ph.D. Vice President, Investor Relations 650-422-7753 investor@dermira.com

Robert H. Uhl Westwicke Partners Managing Director 858-356-5932 robert.uhl@westwicke.com